Decipher Labs

Who are the top shareholders of the Decipher Labs?

The top shareholders of Decipher Labs include Ajjarapu Janakiram with 16.43% and Seshu Srinivas Akula with 3.8%. Individual investors collectively own 80.75% of the shares, with no institutional or pledged promoter holdings reported.

The top shareholders of Decipher Labs include Ajjarapu Janakiram, who holds the largest stake at 16.43%. The highest public shareholder is Seshu Srinivas Akula, with a holding of 3.8%. Additionally, individual investors collectively own a significant portion of the company, accounting for 80.75% of the shares. There are no institutional holdings or pledged promoter holdings reported.

Has Decipher Labs declared dividend?

No Dividend History Available

Who are the peers of the Decipher Labs?

Decipher Labs' peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, and others. While Sun Pharma and Cipla show excellent management and growth, Decipher Labs has below-average growth and capital structure, with a 1-year return of -37.22%.

Peers: The peers of Decipher Labs are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Span Divergent, Unjha Formul., Checkpoint Trend, Vivanza Biosci., and Cian Healthcare.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Average management risk is found at Decipher Labs and Unjha Formul. Below Average management risk is noted for Checkpoint Trend, Vivanza Biosci., and Cian Healthcare. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen at Divi's Lab., Torrent Pharma, Decipher Labs, Unjha Formul., Checkpoint Trend, Vivanza Biosci., and Cian Healthcare. Excellent capital structure is present at Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, while Below Average capital structure is noted for Decipher Labs, and Average capital structure is observed at Unjha Formul. Good capital structure is seen at Torrent Pharma.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while Cian Healthcare has the lowest at -82.59%. Decipher Labs' 1-year return is -37.22%, which is significantly lower than the highest return and higher than the lowest. Additionally, the six-month return is negative for Decipher Labs, Span Divergent, Unjha Formul., and Vivanza Biosci.

Is Decipher Labs overvalued or undervalued?

As of June 2, 2025, Decipher Labs is considered overvalued with a risky valuation grade, reflected by a negative PE ratio of -2.22, an EV to EBITDA of -1.20, and a year-to-date stock return of -24.62%, significantly underperforming its peers and the Sensex.

As of 2 June 2025, Decipher Labs has moved from an attractive to a risky valuation grade. The company is currently considered overvalued based on its financial metrics, with a PE ratio of -2.22, an EV to EBITDA of -1.20, and a ROCE of -38.00%. These figures indicate significant financial distress and lack of profitability, which is further underscored by a negative PEG ratio of 0.00.<BR><BR>In comparison to its peers, Decipher Labs stands out negatively; for instance, Sun Pharma has a PE ratio of 35.25 and an EV to EBITDA of 24.91, while Cipla shows a PE ratio of 22.99 and an EV to EBITDA of 15.93. The stark contrast in these ratios highlights Decipher Labs' struggles within the pharmaceuticals and biotechnology sector. Additionally, the company's stock has underperformed significantly against the Sensex, with a year-to-date return of -24.62% compared to the Sensex's 5.66%, reinforcing the notion that Decipher Labs is overvalued at its current price of 11.27.

What is the technical trend for Decipher Labs?

As of June 4, 2025, Decipher Labs is in a bearish trend with moderate strength, driven by bearish daily moving averages and Bollinger Bands, despite some mildly bullish MACD signals.

As of 4 June 2025, the technical trend for Decipher Labs has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this include the daily moving averages, which are bearish, and the weekly and monthly Bollinger Bands also indicating a bearish trend. Although the MACD shows mildly bullish signals on both weekly and monthly time frames, the overall sentiment is dampened by the bearish moving averages and the Dow Theory, which is mildly bearish on both weekly and monthly scales. The stock's performance has significantly lagged behind the Sensex over various time frames, further supporting the bearish outlook.

Who are in the management team of Decipher Labs?

As of March 2022, the management team of Decipher Labs includes Sushant Mohan Lal (Executive Director), G Venkateswara Rao (Independent Director), and Megha Agarwal (Company Secretary and Compliance Officer).

As of March 2022, the management team of Decipher Labs includes Sushant Mohan Lal, who serves as the Executive Director, G Venkateswara Rao, who is an Independent Director, and Megha Agarwal, who holds the position of Company Secretary and Compliance Officer.

What does Decipher Labs do?

Decipher Labs Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of 35 Cr and a net loss of 41 Cr for the quarter ending March 2025. The company has a market cap of INR 12 Cr and is based in Hyderabad, India.

Overview:<BR>Decipher Labs Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>Decipher Labs Ltd was incorporated as a Private Limited Company in September 1986 and transitioned to a Public Limited Company in June 1992. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 35 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -41 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 12 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.11 <BR>Return on Equity: -22.22% <BR>Price to Book: 0.52<BR><BR>Contact Details:<BR>Address: 4th Flr Plot-94 Sagar Society, Banjara Hills Road No 2 Hyderabad Telangana : 500034 <BR>Email: info@combatdrugs.in <BR>Website: http://www.combatdrugs.in

How big is Decipher Labs?

As of 24th July, Decipher Labs Ltd has a market capitalization of 11.00 Cr and reported net sales of 22.61 Cr with a net loss of 5.08 Cr over the latest four quarters. Shareholder's funds were 21.86 Cr, and total assets were 33.08 Cr as of March 2024.

As of 24th July, Decipher Labs Ltd has a market capitalization of 11.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Decipher Labs reported net sales of 22.61 Cr. However, the company experienced a net loss of 5.08 Cr during the same period.<BR><BR>The latest annual period for the balance sheet is March 2024, where the shareholder's funds amounted to 21.86 Cr, and total assets were reported at 33.08 Cr.

How has been the historical performance of Decipher Labs?

Decipher Labs has experienced a significant decline in net sales and profitability from March 2022 to March 2025, with net sales dropping from 65.32 Cr to 22.61 Cr and operating profit turning negative, resulting in a loss of 5.08 Cr after tax. Total assets and liabilities also decreased during this period, alongside a negative cash flow from operating activities.

Answer:<BR>The historical performance of Decipher Labs shows a significant decline in net sales and profitability over the years, particularly from March 2022 to March 2025.<BR><BR>Breakdown:<BR>Decipher Labs experienced a decrease in net sales from 65.32 Cr in March 2022 to 22.61 Cr in March 2025. This downward trend is reflected in total operating income, which also fell from 65.32 Cr in March 2022 to 22.61 Cr in March 2025. The company's total expenditure, excluding depreciation, peaked at 59.29 Cr in March 2022 but decreased to 29.84 Cr by March 2025. Operating profit (PBDIT) turned negative, going from a profit of 6.03 Cr in March 2022 to a loss of 7.23 Cr in March 2025. Consequently, profit after tax also declined sharply, from 11.38 Cr in March 2022 to a loss of 5.08 Cr in March 2025. The company's total assets decreased from 41.95 Cr in March 2022 to 23.89 Cr in March 2025, while total liabilities also fell from 41.95 Cr to 23.89 Cr in the same period. Cash flow from operating activities showed a negative trend, with a cash outflow of 9.00 Cr in March 2025, compared to a positive inflow of 8.00 Cr in March 2022. Overall, Decipher Labs has faced significant challenges in maintaining sales and profitability over the years.

Are Decipher Labs Ltd latest results good or bad?

Decipher Labs Ltd's latest Q2 FY26 results are concerning, showing a net profit decline of 101.50% year-on-year and a 26.58% drop in revenue, alongside a half-yearly loss of ₹3.41 crores. These metrics indicate significant challenges and a lack of confidence in the company's future prospects.

Decipher Labs Ltd's latest results for Q2 FY26 indicate a troubling financial situation. The company reported a net profit of ₹0.02 crore, which represents a significant decline of 101.50% year-on-year. Revenue also fell sharply, down 26.58% year-on-year to ₹4.31 crores, despite a sequential improvement from the previous quarter.<BR><BR>While there was a slight recovery in operating margins, which improved to 2.78% from deeply negative figures in the prior quarter, this is largely attributed to cost-cutting rather than genuine operational strength. The company's half-yearly performance shows a consolidated loss of ₹3.41 crores, a stark contrast to a profit of ₹0.62 crores in the same period last year.<BR><BR>Overall, the financial metrics reveal a company struggling with sustained revenue erosion and profitability pressures, raising serious concerns about its operational viability. The absence of institutional investment and low promoter holding further reflect a lack of confidence in the company's future prospects. Given these factors, the latest results can be characterized as bad, indicating significant challenges ahead for Decipher Labs.

Should I buy, sell or hold Decipher Labs Ltd?

Why is Decipher Labs Ltd falling/rising?

As of 26-May, Decipher Labs Ltd's stock price is rising to 7.30, reflecting a 3.99% increase after two days of decline, indicating a potential trend reversal. The stock has seen significant investor participation and is currently outperforming its sector, although it remains down year-to-date and over the past year.

As of 26-May, Decipher Labs Ltd's stock price is rising, currently at 7.30, which reflects an increase of 0.28 or 3.99%. This upward movement comes after two consecutive days of decline, indicating a potential trend reversal. The stock has outperformed its sector by 3.95% today, suggesting positive momentum in comparison to its peers. Additionally, there has been a significant increase in investor participation, with a delivery volume of 6.69k on 25 May, which is up by 393.66% against the 5-day average delivery volume. <BR><BR>While the stock has experienced a decline of 30.14% year-to-date and 40.89% over the past year, the current rise in price could be attributed to the recent positive trading activity and the stock's performance relative to the sector. Furthermore, the stock is currently trading higher than its 5-day and 50-day moving averages, although it remains below its 20-day, 100-day, and 200-day moving averages. This indicates a mixed technical picture but highlights a short-term recovery phase. Overall, the combination of increased trading volume and a rebound after previous declines contributes to the current rise in Decipher Labs Ltd's stock price.

Which are the latest news on Decipher Labs?

When is the next results date for Decipher Labs Ltd?

The next results date for Decipher Labs Ltd is 30 May 2026.

The next results date for Decipher Labs Ltd is scheduled for 30 May 2026.